News & Events
Press Releases
April 9, 2021 – Cancer Advances, Inc. Announces Minisymposium Presentation at AACR
Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal cancers, announces that its abstract entitled, “Vaccination with Polyclonal Antibody Stimulator (PAS) prevents pancreatic carcinogenesis in the KRAS mouse...
March 18, 2021 – Cancer Advances, Inc. Announces Abstract at AACR
Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal cancers, announces that an abstract will be included in the upcoming 2021 American Association of Cancer Research (AACR) Annual Meeting being held virtually...
November 11, 2019 – Cancer Advances, Inc. announces a new publication “Vaccine Against Gastrin, a Polyclonal Antibody Stimulator, Decreases Pancreatic Cancer Metastases” in the American Journal of Physiology—Gastrointestinal and Liver Physiology
• Immune competent female mice with pancreatic cancer treated with Polyclonal Antibody Stimulator (PAS) vaccine had significantly smaller tumors and fewer metastases than control mice. • PAS vaccine decreased metastasis by decreasing key pathway proteins involved in...
November 11, 2019 – Cancer Advances, Inc. announces new publication: “Gastrin Vaccine Improves Response to Immune Checkpoint Antibody in Murine Pancreatic Cancer by Altering the Tumor Microenvironment”, in the journal Cancer Immunology, Immunotherapy
• Inactivation of the growth peptide gastrin modulates the tumor microenvironment of pancreatic cancer rendering it more susceptible to immune checkpoint antibody therapy. • Polyclonal Antibody Stimulator (PAS) monotherapy elicits both a humoral and a cellular immune...
Pioneering new medicines and redefining possibilities for cancer patients.
Cancer Advances
Westpark Corporate Center
4364 South Alston Avenue,
Suite 105 Durham, North Carolina
USA 27713
© 2020 Cancer Advances, Inc. All rights reserved.